- Home
- GBR vs EDSA Comparison
GBR vs EDSA Comparison
Compare GBR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- EDSA
- Stock Information
- Founded
- GBR 1978
- EDSA 2015
- Country
- GBR United States
- EDSA Canada
- Employees
- GBR N/A
- EDSA N/A
- Industry
- GBR Oil & Gas Production
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- EDSA Health Care
- Exchange
- GBR Nasdaq
- EDSA Nasdaq
- Market Cap
- GBR 6.1M
- EDSA 6.2M
- IPO Year
- GBR N/A
- EDSA N/A
- Fundamental
- Price
- GBR $1.13
- EDSA $2.43
- Analyst Decision
- GBR
- EDSA Strong Buy
- Analyst Count
- GBR 0
- EDSA 1
- Target Price
- GBR N/A
- EDSA $21.00
- AVG Volume (30 Days)
- GBR 35.9K
- EDSA 5.9M
- Earning Date
- GBR 03-31-2025
- EDSA 02-14-2025
- Dividend Yield
- GBR N/A
- EDSA N/A
- EPS Growth
- GBR N/A
- EDSA N/A
- EPS
- GBR N/A
- EDSA N/A
- Revenue
- GBR $147,000.00
- EDSA N/A
- Revenue This Year
- GBR N/A
- EDSA N/A
- Revenue Next Year
- GBR N/A
- EDSA N/A
- P/E Ratio
- GBR N/A
- EDSA N/A
- Revenue Growth
- GBR N/A
- EDSA N/A
- 52 Week Low
- GBR $0.96
- EDSA $1.55
- 52 Week High
- GBR $1.82
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- GBR 42.66
- EDSA 56.54
- Support Level
- GBR $1.16
- EDSA $2.30
- Resistance Level
- GBR $1.23
- EDSA $4.49
- Average True Range (ATR)
- GBR 0.07
- EDSA 0.30
- MACD
- GBR -0.01
- EDSA 0.05
- Stochastic Oscillator
- GBR 0.00
- EDSA 22.56
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.